Johnson & Johnson (NYSE:JNJ) said Tuesday that it expects its 2024 operation sales growth to grow between 5% and 6% as its psoriasis drug Stelara faces competition in the United States.
Ahead of a meeting with investors, the company guided 2024 adjusted operational earnings per share in the range of $10.55 to $10.75, representing growth of 7.3% at the midpoint.
This guidance includes a $0.15 dilutive impact associated with J&J’s acquisition of Laminar.
For 2025, J&J said it expects an operational sales growth of at least 3% despite the entry of biosimilar drugs to Stelara in the US and a compound annual growth rate between 5% and 7% from 2025 to 2030.
It said it intends to deliver more than 20 new therapies and more than 50 product expansions by 2030.
J&J shares traded down 0.2% at US$158.50 late morning on Tuesday.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie